Research Topics
Species | R KurlanSummaryAffiliation: University of Rochester Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
"Levodopa phobia": a new iatrogenic cause of disability in Parkinson diseaseRoger Kurlan
Department of Neurology, University of Rochester School of Medicine, Rochester, NY 14642, USA
Neurology 64:923-4. 2005- Atomoxetine treatment of ADHD in children with comorbid Tourette syndromeThomas J Spencer
Pediatric Psychopharmacology, Massachusetts General Hospital, Boston, MA 02114 2696, USA
J Atten Disord 11:470-81. 2008..This study examines changes in severity of tics and ADHD during atomoxetine treatment in ADHD patients with Tourette syndrome (TS)... - "Fear of falling" gait: a potentially reversible psychogenic gait disorderRoger Kurlan
University of Rochester School of Medicine and Dentistry, Department of Neurology, Rochester, New York 14620, USA
Cogn Behav Neurol 18:171-2. 2005..To describe "fear of falling" gait... - Disabling repetitive behaviors in Parkinson's diseaseRoger Kurlan
Department of Neurology, University of Rochester School of Medicine, Rochester, New York 14642 8673, USA
Mov Disord 19:433-7. 2004..The repetitive behavior responded poorly to serotonin reuptake inhibitors. Certain atypical antipsychotics may be of benefit... - The pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection (PANDAS) etiology for tics and obsessive-compulsive symptoms: hypothesis or entity? Practical considerations for the clinicianRoger Kurlan
Cognitive and Behavioral Neurology Unit, Department of Neurology, University of Rochester School of Medicine, Rochester, New York 14642 8673, USA
Pediatrics 113:883-6. 2004..The optimum diagnostic and therapeutic approach awaits the results of additional research studies... - Tourette's syndrome: are stimulants safe?Roger Kurlan
Department of Neurology, University of Rochester School of Medicine, 601 Elmwood Avenue, Rochester, NY 14642 8673, USA
Curr Neurol Neurosci Rep 3:285-8. 2003..Methylphenidate appears to be the best-tolerated stimulant compound, with tics often lessening during treatment... - Quetiapine for agitation or psychosis in patients with dementia and parkinsonismRoger Kurlan
Mt Hope Professional Building, Rochester, NY 14620, USA
Neurology 68:1356-63. 2007..To assess the efficacy and tolerability of quetiapine for agitation or psychosis in patients with dementia and parkinsonism... - Prevalence of tics in schoolchildren and association with placement in special educationR Kurlan
Department of Neurology, University of Rochester School of Medicine and Dentistry, NY 14642, USA
Neurology 57:1383-8. 2001.... 
Streptococcal infection and exacerbations of childhood tics and obsessive-compulsive symptoms: a prospective blinded cohort studyRoger Kurlan
University of Rochester School of Medicine, Mt Hope Professional Building, 1351 Mt Hope Ave, Suite 100, Rochester, NY 14620, USA
Pediatrics 121:1188-97. 2008....
A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson diseaseI H Richard
University of Rochester, Rochester, NY, USA
Neurology 78:1229-36. 2012..To evaluate the efficacy and safety of a selective serotonin reuptake inhibitor (SSRI) and a serotonin and norepinephrine reuptake inhibitor (SNRI) in the treatment of depression in Parkinson disease (PD)...- The behavioral spectrum of tic disorders: a community-based studyR Kurlan
Department of Neurology, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Rochester, NY 14642-8673, USA
Neurology 59:414-20. 2002..CONCLUSION: The behavioral spectrum of tic disorders includes OCD, other anxiety disorders, a mood disorder, and attention-deficit and disruptive behavior disorders... - Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuationsRobert A Hauser
Department of Neurology, University of South Florida, Tampa, Florida 33606, USA
Mov Disord 23:2177-85. 2008..We conclude that istradefylline is well tolerated and significantly reduces OFF time as an adjunct to levodopa in PD subjects with motor fluctuations... - Istradefylline as monotherapy for Parkinson disease: results of the 6002-US-051 trialH H Fernandez
Department of Neurology, University of Florida Movement Disorders Center, PO Box 100236, 100 South Newell Dr, L3 100, Gainesville, FL 32610 0236, USA
Parkinsonism Relat Disord 16:16-20. 2010..6002-US-051 was a 12-week, double-blind study evaluating the safety and efficacy of istradefylline, a selective A(2A) adenosine receptor antagonist, as monotherapy in patients with Parkinson's disease (PD)... - The management of ticsDavid Shprecher
Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, NY 14620, USA
Mov Disord 24:15-24. 2009..A comprehensive evaluation accounting for secondary causes, psychosocial factors, and comorbid neuropsychiatric conditions is essential to successful treatment of tic disorders... - Maternal inheritance and mitochondrial DNA variants in familial Parkinson's diseaseDavid K Simon
Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA
BMC Med Genet 11:53. 2010..We investigated the potential contribution of mtDNA variants or mutations to the risk of PD... - Fatigue in levodopa-naive subjects with Parkinson diseaseG Schifitto
University of Rochester, NY, USA
Neurology 71:481-5. 2008..Fatigue is a common complaint in Parkinson disease (PD). We investigated fatigue in a cohort of previously untreated patients with early PD enrolled in the Earlier vs Later Levodopa (ELLDOPA) clinical trial... - Normal pressure hydrocephalus: diagnosis and treatmentDavid Shprecher
University of Rochester School of Medicine, 1351 Mt Hope Avenue, Suite 100, Rochester, NY 14620, USA
Curr Neurol Neurosci Rep 8:371-6. 2008.... - Parkinson's disease and dementia with Lewy bodies: one disease or two?Irene Hegeman Richard
University of Rochester School of Medicine and Dentistry, Department of Neurology, Rochester, New York 14642, USA
Mov Disord 17:1161-5. 2002..The mechanisms responsible for the different clinical presentations are not known, and the issue of whether PD and DLB represent two distinct diseases remains unsettled... - Worsening of motor function and mood in a patient with Parkinson's disease after pharmacologic challenge with oral rivastigmineIrene Hegeman Richard
Department of Neurology, University of Rochester School of Medicine and Dentistry, New York 14642, USA
Clin Neuropharmacol 25:296-9. 2002..We conclude that further studies should be done to evaluate the efficacy and tolerability of these agents in this illness but that caution should be exercised when using acetylcholinesterase inhibitors in patients with PD... - The ups and downs of Parkinson disease: a prospective study of mood and anxiety fluctuationsIrene H Richard
University of Rochester, Rochester, New York, USA
Cogn Behav Neurol 17:201-7. 2004..Parkinson disease (PD) patients with motor fluctuations experience mood fluctuations, but studies have been limited in number and methodology... - Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trialThomas Guttuso
Department of Neurology, University of Rochester, Rochester, New York 14642, USA
Obstet Gynecol 101:337-45. 2003..To evaluate whether treatment with the anticonvulsant gabapentin may be effective in reducing hot flash frequency and severity... - Cancer incidence in a trial of an antiapoptotic agent for Parkinson's diseaseSteven R Schwid
Department of Neurology, University of Rochester, Rochester, New York, USA
Mov Disord 25:1801-8. 2010..Melanoma occurrence in our PD patients was greater than predicted compared with the general population and was unrelated to dopaminergic therapy. Clinical surveillance of PD patients for melanoma may be warranted... - A longitudinal program for biomarker development in Parkinson's disease: a feasibility studyBernard Ravina
Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
Mov Disord 24:2081-90. 2009..The PostCEPT cohort and associated studies strongly support the feasibility of the LABS-PD approach of retaining and repurposing clinical trial cohorts to collect longitudinal clinical and biomarker data... - Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trialRobert G Holloway
Department of Neurology, University of Rochester, 1351 Mt Hope Avenue, Suite 220, Rochester, NY 14620, USA
Arch Neurol 61:1044-53. 2004..The best way to initiate dopaminergic therapy for early Parkinson disease remains unclear... - Tics and its disordersD Marcus
Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642-8673, USA
Neurol Clin 19:735-58, viii. 2001..Tourette syndrome and its differential diagnosis are discussed in this article with a focus on new developments in classification, etiology, epidemiology, genetics, pathophysiology, and clinical management... - Myoclonus-dystonia, obsessive-compulsive disorder, and alcohol dependence in SGCE mutation carriersC W Hess
Department of Neurology, PACC, Beth Israel Medical Center, Suite 5J, 10 Union Square East, New York, NY 10003, USA
Neurology 68:522-4. 2007.... - Relationship between mood and motor fluctuations in Parkinson's diseaseI H Richard
Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
J Neuropsychiatry Clin Neurosci 13:35-41. 2001..Motor and emotional states were not, however, consistently correlated. When they were correlated, the most frequent pattern was the common occurrence of decreased mood, increased anxiety, and reduced motor function... - Levodopa responsiveness in disorders with parkinsonism: a review of the literatureRadu Constantinescu
Department of Neurology, University of Rochester School of Medicine, Rochester, New York, USA
Mov Disord 22:2141-8; quiz 2295. 2007..Efforts should be directed toward better defining LR when used for diagnostic purposes and in scientific publications... - A focus on the synapse for neuroprotection in Alzheimer disease and other dementiasPaul Coleman
Center for Aging and Developmental Biology, University of Rochester School of Medicine, Rochester, NY 14642-8673, USA
Neurology 63:1155-62. 2004..e., "synaptoprotection") in AD. Such "synaptoprotective" therapy will probably need to be administered at a critical early time point, perhaps years before onset of clinical symptoms... - Medication tolerance and augmentation in restless legs syndrome: the need for drug class rotationRoger Kurlan
Movement Disorders Unit, Department of Neurology, University of Rochester School of Medicine, Rochester, NY, USA
J Gen Intern Med 21:C1-4. 2006..We discuss the optimal management of RLS and propose strategies to overcome tolerance and augmentation such as a rotational approach among agents from different classes... - Assistive devices for gait in Parkinson's diseaseRadu Constantinescu
Department of Neurology, University of Rochester School of Medicine, 1351 Mt Hope Avenue, Suite 100, Rochester, NY 14620 3917, USA
Parkinsonism Relat Disord 13:133-8. 2007..We review the available literature and provide practical information about available mobility assistive devices for patients with PD... - Syncope in children with Tourette's syndrome treated with guanfacineAllison King
Department of Neurology, University of Rochester Medical Center, Rochester, New York 14620, USA
Mov Disord 21:419-20. 2006..Syncope appears to be an uncommon side effect of guanfacine and is probably due to drug-induced hypotension or bradycardia... - A new presenilin Alzheimer's disease case confirms the helical alignment of pathogenic mutations in transmembrane domain 5Paul Coleman
Department of Neurology, Center for Aging and Developmental Biology, University of Rochester Medical Center, 601 Elmwood Avenue, P.O. Box 645, NY 14642, USA
Neurosci Lett 364:139-40. 2004..We conclude that the cause of Alzheimer's disease in this patient is an authentic PS1 gene abnormality responsible for the patient's early onset Alzheimer's disease... - Future and alternative therapies in Tourette syndromeRoger Kurlan
Department of Neurology, University of Rochester, Rochester, New York, USA
Adv Neurol 99:248-53. 2006
Research Grants
- PANDAS and Strep Infection: Are they Linked?Roger Kurlan; Fiscal Year: 2004..Disproving the PANDAS hypothesis would prevent the use of expensive and potentially dangerous therapies (e.g., plasma exchange, immune globulin, antibiotics) that have been proposed for PANDAS patients. ..
- Treating Agitation/Psychosis in Dementia/ParkinsonismRoger Kurlan; Fiscal Year: 2004..This study will provide important information regarding the optimal treatment of psychosis and agitation for patients with the commonly encountered combination of primary dementia and parkinsonism. ..
- Parkinson's Disease Data Organizing CenterRoger Kurlan; Fiscal Year: 2007..The University of Rochester has extensive expertise and resources which will facilitate the development of a highly successful PD-DOC. The PD-DOC will be a critical force in advancing collaborative research in PD. ..